Latest Strategy News

WA Kaolin is seeking up to A$34.9 million through a fully underwritten entitlement offer aimed at restructuring its balance sheet, reducing shareholder loans, and funding operational improvements at its Wickepin kaolin project.

Energy Technologies Limited has secured nearly $2 million through a discounted share placement aimed at reducing debt and shoring up working capital amid ongoing financial restructuring.

Eden Innovations attributes recent share price rise to an upcoming US defence forum presentation, confirming no undisclosed material information.

Core Lithium has completed the second tranche of a A$120 million equity raise, securing A$67 million and shareholder approval for convertible notes, positioning the Finniss Lithium Project for continued development.

Mamba Exploration has identified over 20km of gold mineralisation strike at its Meeka East Gold Project, extending the Mulga Bill trend and unveiling new anomalies. The company secured up to $90,000 in co-funding from the WA Government’s Exploration Incentive Scheme to advance drilling plans.

Taiton Resources has finished drilling a single 810m diamond hole at its Yogi prospect within the Highway Project, South Australia, with assay results due in June.

Canyon Resources boosts its control over Cameroon's key rail and port infrastructure with a significant stake increase in Camrail and a strategic investment in the Port of Douala, setting the stage for the Minim Martap bauxite project’s first shipment in late Q3 2026.

Aquirian Limited has secured $8 million through a strongly supported placement to accelerate growth of its Drillforce business and support a major $48 million contract at the Lord Byron mine.

SKS Technologies has landed a $22 million contract to deliver integrated electrical systems for a major retailer's new Melbourne headquarters, pushing its order book to $355 million amid a booming project pipeline.

Classic Minerals faces a full trial in its legal dispute over Forrestania tenements but retains 80% gold rights and asserts claims to full ownership, continuing exploration plans amid uncertainty.

Pengana International Equities (ASX:PIA) unveils a comprehensive capital management plan offering shareholders an equal-access off-market buy-back at after-tax NTA, a fully franked special dividend, and appoints Antipodes Global Investment Management to steer its portfolio.

Amplia Therapeutics and ANZGOG have initiated a clinical trial to test narmafotinib combined with chemotherapy in ovarian cancer patients unresponsive to platinum-based treatment, aiming to improve surgical outcomes and explore biomarker insights.